Research programme - xeroderma pigmentosum group A protein inhibitors - NERx BiosciencesAlternative Names: NERx X80 class of compounds - NERx Biosciences; NERx-X80
Latest Information Update: 04 Oct 2016
At a glance
- Originator NERx Biosciences
- Class Small molecules
- Mechanism of Action DNA repair inhibitors; DNA-binding protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 27 Sep 2016 Preclinical trials in Cancer in USA before September 2016 (NERx Bioscience pipeline, September 2016)
- 15 Mar 2016 Biomarkers information updated